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Introduction 
Syphilis is an infectious disease caused by Treponema pallidum subspecies pallidum. This 
spirochete bacterium is transmitted through sexual contact and from mother to fetus during 
pregnancy or at birth.  
Universal screening for syphilis in pregnancy has been reviewed in the past. In 1998, the 
National Screening Committee (NSC) recommended the continuation of universal antenatal 
screening for syphilis based on the report, produced by the Public Health Laboratory Service and 
the PHLS Syphilis Working Group: "Antenatal syphilis screening in the UK: a systematic review 
and national options appraisal with recommendations" (July 1998). This report assessed the 
question raised by cost-effectiveness analyses that due to the low prevalence of syphilis in the 
UK, universal screening might no longer be necessary.  The review directly addressed the issue 
of whether screening should continue.  However, the authors concluded that due to the 
important and devastating consequences of syphilis in pregnancy, concerns about the potential 
for increases in the incidence of syphilis highlighted by an outbreak in Bristol and increased 
immigration and limited resource savings from withdrawal of the programmethe benefits of 
continuing screening outweighed the cost of such a programme.  In 2007 the results of a 
literature search were considered at a UKNSC / HPA  stakeholder workshop and it was agreed 
that no publications suggested the need to withdraw the programme. 
The current IDPS Programme recommends screening for syphilis so that those with a positive 
test can be clinically assessed and a diagnosis made to determine whether treatment and follow 
up is required.  Infants born to infected mothers who have received adequate penicillin 
treatment during pregnancy are at minimal risk for congenital syphilis. This document was 
developed as part of the UKNSC’s cycle of evidence reviews and summarises the results of an 
external review on syphilis screening in pregnancy, using evidence published since 2007.  A 
particular focus of the review was to establish whether any of publications suggested a need to 
revisit the question of the discontinuation of screening which was addressed by the PHLS in 
1998. 
Appraisal against UK NSC Criteria 
These criteria are available online at http://www.screening.nhs.uk/criteria. 
1. The condition should be an important health problem 
The association of maternal syphilis with poor pregnancy outcomes, including congenital 
syphilis, has been well recognised, although its full characterization was not possible until 
Wasserman’s development of a serologic test in 19062. Our ability to study the impact of 
treatment, now that highly effective treatment is available, is limited by the ethical requirement 
to treat those diagnosed, making existing historical sources of information particularly valuable. 
In 1917, William Osler observed that syphilis accounted for 20% of all stillbirths and 18 to 22% of 
infant deaths in the United States3. Similar neonatal mortality rates were observed in the U.K. in 
that era4.  In a recent systematic review and meta-analysis of historical observational studies, an 
increase of 21% foetal losses and stillbirths, of almost 10% neonatal deaths (before 29 days of 
life), and of 6% among infants born prematurely or with a low birth weight, were estimated in 
syphilitic pregnancies compared to non-syphilitic pregnancies in the absence of treatment5. An 
additional 15% of infants will present with signs and symptoms of syphilis infection. In total, 
66.5% of pregnancies affected by syphilis resulted in adverse outcomes, compared to 14.3% of 
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non-syphilitic pregnancies, in the absence of treatment5. In other words, untreated active 
syphilis in a pregnant woman increases the incidence of adverse outcomes of pregnancy almost 
five-fold.  
2. The epidemiology and natural history of the condition, including 
development from latent to declared disease, should be adequately understood 
and there should be a detectable risk factor, disease marker, latent period or 
early symptomatic stage 
In the UK, surveillance data are available on sexually transmitted diseases since 1917. Since 
2001, such infections are reported to the Health Protection Agency (HPA), through an enhanced 
surveillance system 6.  
Diagnoses of infectious syphilis declined during the 1980s following the primary prevention 
prevention response to the arrival of the HIV/AIDS epidemic. A relatively low level of reported 
diagnoses was maintained in the 1990s throughout the UK. The first recent outbreak of 
infectious syphilis affecting women occurred in Bristol in 1997. This was followed by outbreaks 
in the cities of Manchester, Brighton, Peterborough, London, Newcastle upon Tyne, Glasgow, 
Edinburgh, Walsall and the regions of south Wales and Northern Ireland7. More recently, in 
2011, there have been several new outbreaks reported across the UK 8-13, mainly among young 
heterosexuals. 
Figure 1: Diagnosis of infections syphilis made in genito-urinary clinics, United Kingdom, 2002 - 
2011. 
 
 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
Male 1315 1688 2183 2683 2683 2783 2508 2502 2349 2622 
Female 245 317 443 503 433 424 366 349 293 291 
Total 1560 2005 2626 3186 3116 3207 2874 2851 2650 2915 
 
Note: HPA STI Report 2002 – 2011 
(http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1215589015024)7 
The table shows minor fluctuations in annual reported cases in women and the HPA report an 
increase in the cases of congenital infection14.  The number of cases of syphilis in pregnancy 
requiring treatment and congenital syphilis is currently being investigated by the Surveillance of 
Antenatal Syphilis Screening (SASS) study and a British Paediatric Surveillance Unit (BPSU) study.   
Congenital syphilis is the result of transplacental transmission of spirochetes.  The risk of vertical 
transmission depends primarily on the stage of maternal syphilis and, if the woman is newly 
infected while pregnant, on the stage of the pregnancy. Syphilis infection in the adult evolves 
over time through three symptomatic stages15: 1) primary syphilis follows an incubation period 
of one to four weeks. The typical primary chancre is a single papule.  Both men and women may 
ignore a visible lesion, because it is painless and heals completely in three to six weeks; 2) 
secondary and latent syphilis is a systemic, multi-organ disease that begins six to twelve weeks 
after infection. Mucocutaneous lesions are common and even without treatment, complete 
UK NSC External Review 
Page 4 
resolution of secondary syphilis occurs after three to twelve weeks. The disease then enters a 
latent phase which may last for many years; 3) tertiary syphilis is marked by destructive lesions. 
The manifestations are divided into three main subgroups: neurosyphilis, cardiovascular syphilis, 
and late benign syphilis (gummas). 
Mother-to-child transmission is higher (60% to 90%) in untreated maternal primary or secondary 
syphilis, decreasing to 40% in early latent syphilis, and to <10% in late latent syphilis15.  
3. All the cost-effective primary prevention interventions should have been 
implemented as far as practicable 
Primary prevention of congenital syphilis relies on prevention strategies to avoid sexual 
transmission of syphilis among adults of reproductive age. There are no primary prevention 
programmes for syphilis in isolation from other sexually transmitted infections. Preventing 
sexual transmission of syphilis relies on general primary prevention programmes for sexually 
transmitted infections, including HIV. These interventions were successful in the 1990s but, as 
shown by the re-emergence of syphilis in the general population, they have had mixed results 
more recently. As such, relying on primary prevention programmes alone is currently 
inadequate to prevent transmission occurring in pregnancy. 
 
4. If the carriers of a mutation are identified as a result of screening the natural 
history of people with this status should be understood, including the 
psychological implications. 
Not applicable. 
5. There should be a simple, safe, precise and validated screening test 
Currently, antenatal screening for syphilis is a well established component of the Infectious 
Diseases in Pregnancy Screening Programme, where pregnant women are offered tests for 
hepatitis B, HIV, syphilis and rubella susceptibility16.  
The most commonly used method to diagnose syphilis is serology. Serologic tests include 
treponemal and nontreponemal tests. Nontreponemal tests (e.g. RPR or VDRL) detect 
antibodies present from 4 to 8 weeks after infection onwards. These tests can be quantified by 
serial serum dilution and changes in titres can help indicate successful treatment. Treponemal 
tests (e.g. FTA-ABS, MHA-TP, and TPPA) are reactive slightly earlier than nontreponemal tests 
and patients remain seroreactive for life, even if successfully treated. False-positive treponemal 
tests can be seen in various conditions, especially spirochetal infections, including Lyme disease 
(in which the nontreponemal test shows negative results)15. 
 
The tests used to define seroreactivity vary across settings and over time, from the Wasserman 
and Kahn tests (for which sensitivity and specificity data are not available) in early studies to the 
Venereal Disease Research Laboratory or rapid plasma reagin tests (sensitivity, 71–100%; 
specificity, 98%), the fluorescent treponemal antibody absorption test (sensitivity, 84–100%; 
specificity, 97%) and the microhaemagglutination assay for T. pallidum (sensitivity, 76–100%; 
specificity, 99%) in more recent studies.47 
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The UK-recommended screening procedure for syphilis includes a highly sensitive test to detect 
antibodies (Enzyme immunoassay, EIA), followed by a highly sensitive and specific confirmatory 
treponemal test (Treponema pallidum particle agglutination (TPPA) or Treponema pallidum 
haemagglutination (TPHA))17. The use of EIAs in the UK has been reported to have the advantage 
of producing objective results since there is linkage of EIA plate readings directly to laboratory 
computer systems18.  The reported sensitivity and specificity of treponemal EIAs is high, ranging 
from 85 – 99.5% and 98.3 – 100%.48 
 
Similar recommendations are found in the United States, where two tests are used in sequence: 
one to screen and the other one to confirm infection. However, in the United States the initial 
screening includes the non-treponemal tests such as Venereal Disease Research Laboratory 
(VDRL) and the Rapid plasma regain (RPR); followed by confirmatory treponemal tests 
(fluorescent treponemal antibody absorbed (FTA-ABS) and the Treponema pallidum particle 
agglutination (TPPA))19. 
Recently, newer treponemal-based EIAs and chemoluminiscence immunoassays have been 
released. The following  tests are being evaluated and are not currently recommended within 
the UK screening programme:  
The LIAISON Treponema Screen, Enzygnost Syphilis, and the ARCHITECT Syphilis TP have 
demonstrated sensitivity and specificity when evaluated as a confirmatory test and as a 
screening test for syphilis among various patient populations. However, the use of a 
confirmatory test, such as TPHA, remains prudent in order to avoid false-positive results20-24. 
Although IMMULITE 2000 syphilis screen uses a single p17 antigen, it was found to be more 
sensitive than the Bioelisa SYPHILIS 3.0 which uses three recombinant antigens (p15, p17 and 
p47). IMMULITE 200 Syphilis Screen was found to be a specific and sensitive method of syphilis 
screening and could be considered as alternative to other ELISA tests25. It was shown to be 
comparable to the TPPA, with the advantage of being a fully automated system26. 
Captia Select-Syph-G ELISA was evaluated focusing on discrepancies between the results of IgG 
ELISA and the TPHA tests. The authors found it to be a reliable tool for syphilis testing in high-
risk population and recommended its use as a confirmatory test in at-risk patients.27 
6. The distribution of test values in the target population should be known and 
a suitable cut-off level defined and agreed 
Screening tests, confirmatory tests and guidelines for the reporting of results are available in the 
Infectious Diseases in Pregnancy Screening programme – handbook for laboratories17.  
In 2009 1,142 screen positive test results were reported to the HPA National Antenatal 
Infections Screening Monitoring Programme (reference IDPS Annual Report 2010 – 11).  
However these reports do not distinguish between new diagnoses, false positives, other 
infections and previously treated infections.  This issue is currently being explored within the 
Surveillance of Antenatal Syphilis Screening (SASS).  Emerging data suggests that 24% may be 
new diagnoses and 43% previously treated infections (personal communication, SASS study).  
This will be more fully reported following completion of the study and analysis of the data. 
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7. The test should be acceptable to the population 
Current practice guidelines recommend that all pregnant women are offered screening for 
syphilis early in pregnancy alongside the other antenatal booking blood tests as part of the 
Infectious Diseases in Pregnancy Screening Programme16. The work of this programme and 
reported uptake rates of over 95%28 29 implies that the syphilis screening tests are acceptable to 
pregnant women.  
8. There should be an agreed policy on the further diagnostic investigation of 
individuals with a positive test result and on the choices available to those 
individuals 
Guidelines for the assessment and management of syphilis in pregnancy and infancy have 
recently been developed by British Association for Sexual Health and HIV (BASHH) and these 
represent best management practice30. In these guidelines, it is recommended that all pregnant 
women are offered screening for syphilis at the initial antenatal visit. All women with positive 
syphilis screening test results should be offered testing for other Sexually Transmitted Infections  
including HIV. With regards to treatment recommended, briefly, a single dose of benzathine 
penicillin G 2.4MU is effective in most cases of syphilis during pregnancy although failures have 
been reported, mainly in those at increased risk of transmission (higher RPR/VDRL titre, early 
stage maternal disease and last trimester treatment). When maternal treatment is initiated in 
the third trimester a second dose of benzathine penicillin is recommended 1 week after the first, 
with careful assessment. Retreatment in those with a previous diagnosis of syphilis should be 
considered when there is uncertainty of efficacious past treatment. Non-penicillin alternatives 
include ceftriaxone and erythromycin or azithromycin. Desensitization to penicillin in those 
reporting allergies should be considered. Multidisciplinary management is recommended, with a 
close liaison with obstetric, midwifery and paediatric colleagues. Referral to fetal medicine for 
ultrasound to evaluate fetal involvement and fetal monitoring for fetal distress in the early 
stages of therapy is recommended after 26 weeks gestation. 
9. If the test is for mutations the criteria used to select the subset of mutations 
to be covered by screening, if all possible mutations are not being tested, 
should be clearly set out 
Not applicable. 313233 
10. There should be an effective treatment or intervention for patients 
identified through early detection, with evidence of early treatment leading to 
better outcomes than late treatment 
Observational studies show a lower prevalence of any adverse outcome among pregnant 
women who received an intervention (to include screening and treatment for syphilis) in the 
first and second trimesters compared to those women who did not receive screening and 
treatment until the third trimester31-35. For example, Zhu et al, Watson-Jones et al and Carles et 
al reported a higher prevalence of adverse outcomes when women were treated or tested in the 
third trimester compared to earlier in pregnancy (19 vs 27.8, 13.4 vs 21.1, and 13.2 vs 68.8 
respectively)313233. 
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11. There should be agreed evidence based policies covering which individuals 
should be offered treatment and the appropriate treatment to be offered 
Guidelines for the assessment and management of syphilis in pregnancy and infancy have 
recently been developed by BASHH and these represent best management practice30 
12. Clinical management of the condition and patient outcomes should be 
optimised in all health care providers prior to participation in a screening 
programme 
This criterion is not directly applicable as there is an ongoing screening programme.  The IDPS 
Programme standards and BASHH guideline emphasise the need for quick laboratory 
turnaround times and prompt referral of women with screen positive results and robust 
communication between GUM and the referring maternity unit.  A number of issues relating to 
these points are worth noting.   
For example a recent national audit of laboratory diagnostic methods for syphilis showed that 
24% of positive antenatal syphilis screening results were not returned to antenatal clinics within 
2 weeks, and some respondents reported turnaround times in excess of 3 weeks.44 The declining 
number of health professionals with knowledge of syphilis and its management has also been 
noted.45, 46 
 
An audit from one UK GUM clinic recently noted that ‘the average time between a positive test 
and review in AN clinic was 25 days and that between positive test and review in GUM was 35 
days.’  The report also found that communication between GUM and maternity services was an 
area requiring further exploration and protocol development.28  Similarly, emerging information 
from the Surveillance of Antenatal Syphilis Screening study suggests that some units are unable 
to provide information on diagnosis and treatment of women who screened positive for syphilis 
in pregnancy, even after the women have delivered. This appears to relate to a lack of 
communication between the maternity units and the GUM clinics to which the women were 
referred, with issues around confidentiality sometimes cited.  This issue will be more fully 
explored when the study is complete and the data analysed. (personal communication, SASS 
study) 
13. There should be evidence from high quality Randomised Controlled Trials 
that the screening programme is effective in reducing mortality or morbidity. 
Where screening is aimed solely at providing information to allow the person 
being screened to make an “informed choice” (eg. Down’s syndrome, cystic 
fibrosis carrier screening), there must be evidence from high quality trials that 
the test accurately measures risk. The information that is provided about the 
test and its outcome must be of value and readily understood by the individual 
being screened 
A recent review of syphilis screening interventions confirmed that syphilis screening 
programmes coupled with appropriate, prompt penicillin treatment for women testing positive 
are efficacious in reducing adverse pregnancy outcomes, particularly rates of stillbirth and 
perinatal death36. This review did not identify randomised controlled trials of screening because 
UK NSC External Review 
Page 8 
syphilis screening programmes are well established and it would be considered unethical to do 
such a trial. 
A Cochrane review updated in 2010 aimed to identify the most effective antibiotic treatment 
regimen of syphilis in pregnancy37. The authors found no randomised controlled trials to review. 
However, from the observational studies identified, they concluded that both duration and 
dosage were important considerations, re-treatment rates were lowest for primary infections 
and highest for patients with second-stage infection, and that long-acting preparations were 
probably as effective as regimens using multiple injections of aqueous crystalline or procaine 
penicillin G. 
 
14. There should be evidence that the complete screening programme (test, 
diagnostic procedures, treatment/ intervention) is clinically, socially and 
ethically acceptable to health professionals and the public 
The work of the Infectious Diseases in Pregnancy Screening Programme16,the guidelines for the 
assessment and management of syphilis in pregnancy and infancy by BASHH representing best 
management practice30 and the high uptake of screening implies that the syphilis screening 
tests, the diagnosis procedures and the treatment are acceptable to both pregnant women and 
the health care professions.  
However the communication issues discussed in criterion 12 may suggest that the practical 
requirements of an antenatal screening programme are ethically challenging to some 
professionals. 
15. The benefit from the screening programme should outweigh the physical 
and psychological harm (caused by the test, diagnostic procedures and 
treatment) 
Potential harms may include false-positive results that require clinical evaluation (unnecessary 
utilisation of resources), unnecessary anxiety to the patient in case of false-positive result, and 
unnecessary use of antibiotics.  There is also evidence of the women experiencing fear of 
gender-based violence from a partner following the disclosure of sexually transmitted infection 
status38.  
Strategies to overcome such potential harms include: use of highly sensitive and specific 
diagnostic testing; and identifying women at potential increased risk of violence from an 
intimate partner when giving them a positive diagnosis. Such women have been shown to prefer 
provider-initiated referral mechanisms (rather than patient-initiated), and may need additional 
counselling and support strategies to be implemented39.  
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16. The opportunity cost of the screening programme (including testing, 
diagnosis and treatment, administration, training and quality assurance) should 
be economically balanced in relation to expenditure on medical care as a whole 
(ie. value for money). Assessment against this criteria should have regard to 
evidence from cost benefit and/or cost effectiveness analyses and have regard 
to the effective use of available resource 
Syphilis testing coupled with appropriate, prompt penicillin treatment for women testing 
positive has been recognized to be highly cost-effective even in moderate and low prevalence 
settings40 - in agreement with the conclusion of the Public Health Laboratory Service and the 
PHLS Syphilis Working Group: "Antenatal syphilis screening in the UK: a systematic review and 
national options appraisal with recommendations" (July 1998) supporting their recommendation 
to continue universal screening of syphilis in pregnancy in the UK. 
 
No UK studies of cost effectiveness studies were retrieved by the literature search for this 
review. 
 
17. All other options for managing the condition should have been considered 
(eg. improving treatment, providing other services), to ensure that no more 
cost effective intervention could be introduced or current interventions 
increased within the resources available 
Several strategic alternatives to universal antenatal screening for syphilis have been assessed in 
the past.  These included the targeting of the screening programme to pregnant women in high 
risk groups and discontinuing the screening programme entirely.  It was concluded that 
antenatal screening of syphilis should continue in the UK41.  
No publications, retrieved by the literature search, revisited this question. 
18. There should be a plan for managing and monitoring the screening 
programme and an agreed set of quality assurance standards 
Governance of the syphilis screening component is part of the overall governance of the 
Infectious Disease in Pregnancy Screening programme. Across the English National Screening 
Programmes, Key Performance Indicators (KPIs) are now collected to monitor local performance 
of the Infectious Diseases in Pregnancy Screening programme42. However, there is no KPI related 
to syphilis screening. The only two KPIs available to date are: 1) HIV coverage (first return 
31/12/2011), and 2) Timely referral of hepatitis B positive women for specialist assessment (first 
return 30/06/2011).  
19. Adequate staffing and facilities for testing, diagnosis, treatment and 
programme management should be available prior to the commencement of 
the screening programme 
Not directly assessed.  
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20. Evidence-based information, explaining the consequences of testing, 
investigation and treatment, should be made available to potential participants 
to assist them in making an informed choice 
As specified in the National Infectious Diseases in Pregnancy Screening Programme standards16: 
Informed consent for screening must be given before a specimen is taken and tests requested. 
The midwife should ensure that the woman has seen the written information, “Screening tests 
for you and your baby”, or has access to it in a format appropriate to their requirements.   
21. Public pressure for widening the eligibility criteria for reducing the screening 
interval, and for increasing the sensitivity of the testing process, should be 
anticipated. Decisions about these parameters should be scientifically 
justifiable to the public 
n/a 
 22. If screening is for a mutation the programme should be acceptable to 
people identified as carriers and to other family members 
n/a 
Conclusions 
Syphilis continues to occur in women of reproductive age and, as such, there is a continuing risk 
of congenital infection. 
No publications, retrieved by the literature search, suggested that there should be a change in 
the current screening policy. 
Syphilis screening during pregnancy is a cost-effective intervention for which the benefits 
currently outweigh the harms. 
Implications for policy 
A change to the UK NSC’s policy position is not supported by the literature covered in this 
review. 
Implications for research 
Syphilis screening in pregnancy is well-established and seems to be acceptable to both pregnant 
women and to health care providers. Although we do not recommend any change to the current 
UK NSC policy position (to screen all pregnant women), consideration could be given to the 
following issues: 
1. Evaluation of single platform HIV/syphilis screening tests – these are currently under 
development. Their use as point of care diagnostics may help improve efficiency of 
testing procedures. 
2. Studies and audits of issues relating to the interaction between GUM and maternity 
services  
3. Studies and audits of issues relating to and affecting laboratory turnaround times 
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Methodology 
Search strategy 
<Details to be entered by UK NSC> 
 
Quality 
All abstract were reviewed. Abstracts were then classified by relevance to UK context. The 
quality of the evidence was assessed for each publication included by study design and quality. 
Comparisons were made across studies for consistency in results and potential differences in 
populations. 
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